Ono Pharmaceutical Co., Ltd. (OPHLF) Análisis de Acciones
Solo con fines informativos. No es asesoramiento financiero. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
OPHLF representa a Ono Pharmaceutical Co., Ltd., una empresa del sector Healthcare con un precio de $ (capitalización de mercado 0). La acción obtiene una puntuación de 59/100, una calificación moderada basada en 9 KPI cuantitativos.
Ultimo analisis: 15 mar 2026Ono Pharmaceutical Co., Ltd. (OPHLF) Resumen de Asistencia Médica y Tuberías
Ono Pharmaceutical Co., Ltd., established in 1717, develops and markets pharmaceutical products and diagnostic reagents globally. With a diverse portfolio spanning oncology, diabetes, and immunology, the company maintains a strong presence in the healthcare sector, supported by collaborations and a robust pipeline, and currently has a market capitalization of $6.58 billion.
Tesis de Inversión
Ono Pharmaceutical presents a compelling investment case based on its established market presence, diverse product portfolio, and strategic collaborations. With a P/E ratio of 17.79 and a profit margin of 12.3%, the company demonstrates financial stability. Growth catalysts include the expansion of existing product lines like Opdivo and Forxiga, as well as the development of new therapies in its pipeline. The company's dividend yield of 3.39% offers an attractive return for investors. However, potential risks include regulatory hurdles, competition from other pharmaceutical companies, and the inherent uncertainties of drug development. The company's beta of 0.10 suggests low volatility compared to the overall market.
Basado en las finanzas de FMP y el análisis cuantitativo
Puntos clave
- Market capitalization of $6.58 billion indicates substantial company size and investor confidence.
- P/E ratio of 17.79 suggests a reasonable valuation compared to earnings.
- Profit margin of 12.3% demonstrates the company's ability to generate profit from its revenue.
- Gross margin of 69.8% reflects efficient cost management in the production and sales of pharmaceuticals.
- Dividend yield of 3.39% provides a steady income stream for investors.
Competidores y Pares
Fortalezas
- Innovative drug pipeline
- Strong market position in Japan
- Strategic collaborations with leading research institutions
- Diverse product portfolio
Debilidades
- Reliance on a few key products
- Limited presence in some emerging markets
- Exposure to generic competition
- OTC listing may limit access to capital
Catalizadores
- Upcoming: Clinical trial results for novel therapies in the pipeline.
- Upcoming: Regulatory approvals for new indications of existing drugs.
- Ongoing: Expansion of strategic collaborations and partnerships.
- Ongoing: Increasing demand for pharmaceutical products in emerging markets.
- Ongoing: Development of digital health solutions to improve patient outcomes.
Riesgos
- Potential: Regulatory changes and pricing pressures could impact revenue.
- Potential: Competition from other pharmaceutical companies could erode market share.
- Potential: Patent expirations could lead to generic competition.
- Ongoing: The inherent uncertainties of drug development could result in clinical trial failures.
- Ongoing: Economic downturns could reduce demand for pharmaceutical products.
Oportunidades de crecimiento
- Expansion of Opdivo's Indications: Ono Pharmaceutical has the opportunity to expand the approved indications for Opdivo, its leading oncology drug. This includes pursuing approvals for new cancer types and combination therapies. The global oncology market is projected to reach $286.6 billion by 2031, providing a substantial market for Opdivo's continued growth. Timeline: Ongoing clinical trials and regulatory submissions.
- Development of Novel Therapies: Ono Pharmaceutical's pipeline includes several promising drug candidates targeting various diseases, including autoimmune disorders, neurological conditions, and other cancers. Successful development and commercialization of these therapies could significantly boost revenue. The market for autoimmune disease treatments is expected to reach $150 billion by 2028. Timeline: Clinical trials in progress with potential launches in the next 3-5 years.
- Strategic Collaborations and Acquisitions: Ono Pharmaceutical can pursue strategic collaborations and acquisitions to expand its product portfolio and geographic reach. Partnering with biotech companies and research institutions can accelerate drug development and access new technologies. The company's existing collaborations with Adimab LLC and Turbine Ltd. demonstrate its commitment to this strategy. Timeline: Ongoing, with potential deals announced in the next 1-2 years.
- Geographic Expansion: Ono Pharmaceutical can expand its presence in emerging markets, such as China and India, where there is a growing demand for pharmaceutical products. This includes establishing local manufacturing facilities and distribution networks. The pharmaceutical market in emerging economies is expected to grow at a faster rate than developed markets. Timeline: Gradual expansion over the next 5-10 years.
- Digital Health Integration: Ono Pharmaceutical can leverage digital health technologies, such as telemedicine and mobile health apps, to improve patient outcomes and enhance its market reach. This includes developing digital therapeutics and remote monitoring solutions. The digital health market is projected to reach $660 billion by 2028. Timeline: Pilot programs and partnerships in the next 2-3 years, followed by broader implementation.
Oportunidades
- Expansion into new therapeutic areas
- Increased demand for pharmaceutical products in emerging markets
- Development of personalized medicine
- Leveraging digital health technologies
Amenazas
- Regulatory changes and pricing pressures
- Competition from other pharmaceutical companies
- Patent expirations
- Economic downturns
Ventajas competitivas
- Patented pharmaceutical products provide market exclusivity.
- Strong brand reputation in key therapeutic areas.
- Established relationships with healthcare providers and distributors.
- Extensive research and development capabilities.
Acerca de OPHLF
Ono Pharmaceutical Co., Ltd. is a global pharmaceutical company headquartered in Osaka, Japan, with a history stretching back to its founding in 1717. Initially a pharmaceutical wholesaler, the company transitioned to research and development, focusing on innovative drugs. Today, Ono Pharmaceutical develops, manufactures, and markets a wide range of pharmaceutical products and diagnostic reagents across several therapeutic areas, including oncology, diabetes, immunology, and neurology. Key products include Opdivo, an intravenous infusion for malignant tumors, and Glactiv, a tablet for type 2 diabetes. The company also offers treatments for chemotherapy-induced nausea, pheochromocytoma, and other conditions. Ono Pharmaceutical has expanded its global reach through strategic collaborations with companies like Adimab LLC, Turbine Ltd., Sibylla Biotech and academic institutions such as Harvard University. These collaborations enhance its research and development capabilities, allowing it to explore new therapeutic targets and technologies. The company's commitment to innovation and patient care has solidified its position as a key player in the pharmaceutical industry.
Qué hacen
- Develops and markets pharmaceutical products and diagnostic reagents.
- Offers prescription drugs for oncology, diabetes, immunology, and neurology.
- Conducts research and development to discover new therapeutic targets.
- Manufactures pharmaceutical products in compliance with regulatory standards.
- Collaborates with other companies and research institutions to accelerate drug development.
- Distributes its products globally through a network of distributors and partners.
- Provides patient support programs to improve adherence and outcomes.
Modelo de Negocio
- Develops and patents innovative pharmaceutical products.
- Generates revenue through the sale of prescription drugs.
- Invests in research and development to create new products.
- Partners with other companies to expand its product portfolio and geographic reach.
Contexto de la Industria
Ono Pharmaceutical operates within the global pharmaceutical industry, a sector characterized by intense competition, stringent regulations, and high research and development costs. The market is driven by an aging population, increasing prevalence of chronic diseases, and technological advancements in drug discovery. Ono Pharmaceutical competes with major pharmaceutical companies, including DSRLF (Daiichi Sankyo), FLMNF (Fuji Pharma), GZPHF (Guangzhou Baiyunshan Pharmaceutical), HKMPF (Lee's Pharmaceutical), and HKMPY (Hutchison Medipharma), all vying for market share in key therapeutic areas. The company's focus on innovative therapies and strategic collaborations positions it to capitalize on the growing demand for advanced medical treatments.
Clientes Clave
- Hospitals and clinics
- Pharmacies
- Patients with various medical conditions
- Healthcare providers
Finanzas
Gráfico e información
Precio de la acción de Ono Pharmaceutical Co., Ltd. (OPHLF): Price data unavailable
Últimas noticias
-
Ono Pharma Announces New Drug Discovery Collaboration with Congruence Therapeutics in the Priority Areas of Neurology and Immunology
businesswire.com · 2 mar 2026
-
Deciphera Pharmaceuticals Announces U.S. Food and Drug Administration Acceptance for Filing of New Drug Application for Tirabrutinib in Patients with Relapsed or Refractory PCNSL
businesswire.com · 17 feb 2026
Consenso de analistas
Calificación de Consenso
Recomendaciones agregadas de Compra/Mantener/Vender de Benzinga, Yahoo Finance y Finnhub para OPHLF.
Objetivos de Precios
Análisis del precio objetivo de Wall Street para OPHLF.
MoonshotScore
¿Qué significa esta puntuación?
El MoonshotScore califica el potencial de crecimiento de OPHLF en una escala de 0 a 100 en múltiples factores, incluyendo innovación, disrupción del mercado, salud financiera e impulso.
Últimas Noticias
Ono Pharma Announces New Drug Discovery Collaboration with Congruence Therapeutics in the Priority Areas of Neurology and Immunology
Deciphera Pharmaceuticals Announces U.S. Food and Drug Administration Acceptance for Filing of New Drug Application for Tirabrutinib in Patients with Relapsed or Refractory PCNSL
Información del mercado OTC de OPHLF
The OTC Other tier represents the lowest tier of the OTC market, indicating that Ono Pharmaceutical may not meet the minimum financial or disclosure requirements of the higher tiers, such as OTCQX or OTCQB. Companies in this tier may have limited financial reporting and may not be subject to the same level of regulatory scrutiny as companies listed on major exchanges like the NYSE or NASDAQ. This can result in increased risks for investors due to the potential for less transparency and greater information asymmetry.
- Nivel OTC: OTC Other
- Estado de divulgación: Unknown
- Limited financial disclosure
- Lower trading volume and liquidity
- Potential for price manipulation
- Increased regulatory scrutiny
- Higher risk of fraud or mismanagement
- Verify the company's financial statements and SEC filings (if any).
- Research the company's management team and their track record.
- Assess the company's business model and competitive landscape.
- Evaluate the company's legal and regulatory compliance.
- Review the company's investor relations materials and communications.
- Check for any news articles or reports about the company's activities.
- Consult with a financial advisor before investing.
- Established history dating back to 1717
- Global presence and partnerships
- Diverse product portfolio
- Focus on research and development
- Market capitalization of $6.58 billion
Acciones de Ono Pharmaceutical Co., Ltd.: Preguntas Clave Respondidas
¿Cuáles son los factores clave para evaluar OPHLF?
Ono Pharmaceutical Co., Ltd. (OPHLF) actualmente tiene una puntuación IA de 59/100, indicando puntuación moderada. Fortaleza clave: Innovative drug pipeline. Riesgo principal a monitorear: Potential: Regulatory changes and pricing pressures could impact revenue.. Esto no es asesoramiento financiero.
¿Qué es el MoonshotScore de OPHLF?
OPHLF actualmente puntúa 59/100 (Grado C) en el MoonshotScore, lo que sugiere calificación moderada. La puntuación evalúa el potencial de crecimiento, la salud financiera, el impulso del mercado y los factores de riesgo en 9 KPIs cuantitativos. Se recalcula diariamente con los últimos datos del mercado. Esta puntuación es solo informativa.
¿Con qué frecuencia se actualizan los datos de OPHLF?
Los precios de OPHLF se actualizan en tiempo real durante el horario del mercado estadounidense (9:30-16:00 ET, días laborables). Los fundamentales se actualizan después de los informes trimestrales o anuales. Las calificaciones de analistas y las perspectivas de IA se actualizan diariamente. Las noticias se agregan continuamente de fuentes financieras.
¿Qué dicen los analistas sobre OPHLF?
La cobertura de analistas para OPHLF incluye calificaciones de consenso (compra, mantener, venta), objetivos de precio a 12 meses y estimaciones de ganancias de las principales firmas de investigación. Consulte la sección de Consenso de Analistas en esta página.
¿Cuáles son los riesgos de invertir en OPHLF?
Las categorías de riesgo para OPHLF incluyen riesgo de mercado, riesgo específico de la empresa (gestión, competencia), riesgo financiero (deuda, consumo de efectivo) y riesgo macroeconómico (tasas, inflación). Un riesgo clave identificado: Potential: Regulatory changes and pricing pressures could impact revenue.. Un beta superior a 1,0 indica mayor volatilidad que el S&P 500. Revise la sección de Factores de Riesgo en esta página. Todas las inversiones conllevan riesgo de pérdida.
¿Cuál es la relación P/E de OPHLF?
La relación P/E para OPHLF compara el precio actual de la acción con sus ganancias por acción. Un P/E más alto puede indicar expectativas de crecimiento, mientras que un P/E más bajo puede sugerir valor. Consulte la pestaña de Financieros para métricas actuales.
¿Está OPHLF sobrevalorada o infravalorada?
Determinar si Ono Pharmaceutical Co., Ltd. (OPHLF) está sobrevalorada o infravalorada requiere examinar múltiples métricas. Compare los ratios de valoración (P/E, P/S, EV/EBITDA) con pares del sector. Esto no es asesoramiento financiero.
¿Cuál es el rendimiento por dividendo de OPHLF?
Ono Pharmaceutical Co., Ltd. (OPHLF) actualmente no paga un dividendo regular, o los datos de rendimiento no están disponibles. Consulte la pestaña de Financieros para información actual.
Descargo de responsabilidad: Este contenido es solo para fines informativos y no constituye asesoramiento de inversión. Siempre haga su propia investigación y consulte a un asesor financiero.
Recursos Oficiales
Datos proporcionados solo con fines informativos.
- Financial data is based on available information and may be subject to change.
- OTC market data may be limited or incomplete.
- AI analysis is pending and will provide further insights.